Mehra R - Search Results

1

The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.

Epstein JI, Amin MB, Fine SW, Algaba F, Aron M, Baydar DE, Beltran AL, Brimo F, Cheville JC, Colecchia M, Comperat E, da Cunha IW, Delprado W, DeMarzo AM, Giannico GA, Gordetsky JB, Guo CC, Hansel DE, Hirsch MS, Huang J, Humphrey PA, Jimenez RE, Khani F, Kong Q, Kryvenko ON, Kunju LP, Lal P, Latour M, Lotan T, Maclean F, Magi-Galluzzi C, Mehra R, Menon S, Miyamoto H, Montironi R, Netto GJ, Nguyen JK, Osunkoya AO, Parwani A, Robinson BD, Rubin MA, Shah RB, So JS, Takahashi H, Tavora F, Tretiakova MS, True L, Wobker SE, Yang XJ, Zhou M, Zynger DL, Trpkov K. Epstein JI, et al. Among authors: mehra r. Arch Pathol Lab Med. 2021 Apr 1;145(4):461-493. doi: 10.5858/arpa.2020-0015-RA. Arch Pathol Lab Med. 2021. PMID: 32589068 Free article. Review.

2

Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.

Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ. Shah RB, et al. Among authors: mehra r. Cancer Res. 2004 Dec 15;64(24):9209-16. doi: 10.1158/0008-5472.CAN-04-2442. Cancer Res. 2004. PMID: 15604294

3

Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.

Witkiewicz AK, Varambally S, Shen R, Mehra R, Sabel MS, Ghosh D, Chinnaiyan AM, Rubin MA, Kleer CG. Witkiewicz AK, et al. Among authors: mehra r. Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1418-23. doi: 10.1158/1055-9965.EPI-04-0607. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 15941950

4

Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.

Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET. Fu Z, et al. Among authors: mehra r. Prostate. 2006 Feb 15;66(3):248-56. doi: 10.1002/pros.20319. Prostate. 2006. PMID: 16175585 Free article.

5

Autoantibody signatures in prostate cancer.

Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM. Wang X, et al. Among authors: mehra r. N Engl J Med. 2005 Sep 22;353(12):1224-35. doi: 10.1056/NEJMoa051931. N Engl J Med. 2005. PMID: 16177248 Free article.

6

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Tomlins SA, et al. Among authors: mehra r. Science. 2005 Oct 28;310(5748):644-8. doi: 10.1126/science.1117679. Science. 2005. PMID: 16254181

7

Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.

Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM. Varambally S, et al. Among authors: mehra r. Cancer Cell. 2005 Nov;8(5):393-406. doi: 10.1016/j.ccr.2005.10.001. Cancer Cell. 2005. PMID: 16286247 Free article.

8

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, Chinnaiyan AM. Tomlins SA, et al. Among authors: mehra r. Cancer Res. 2006 Apr 1;66(7):3396-400. doi: 10.1158/0008-5472.CAN-06-0168. Cancer Res. 2006. PMID: 16585160

9

Whole transcriptome amplification for gene expression profiling and development of molecular archives.

Tomlins SA, Mehra R, Rhodes DR, Shah RB, Rubin MA, Bruening E, Makarov V, Chinnaiyan AM. Tomlins SA, et al. Among authors: mehra r. Neoplasia. 2006 Feb;8(2):153-62. doi: 10.1593/neo.05754. Neoplasia. 2006. PMID: 16611408 Free PMC article.

10

Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.

Kunju LP, Mehra R, Snyder M, Shah RB. Kunju LP, et al. Among authors: mehra r. Am J Clin Pathol. 2006 May;125(5):675-81. doi: 10.1309/V1RY-91NK-X5AR-W2Q5. Am J Clin Pathol. 2006. PMID: 16707367

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,115 results

Search Page